In recent trading session, Revance Therapeutics Inc (NASDAQ:RVNC) saw 0.68 million shares changing hands at last check today with its beta currently measuring 0.84. Company’s recent per share price level of $3.74 trading at -$0.04 or -0.93% at last check today assigns it a market valuation of $392.86M. That most recent trading price of RVNC’s stock is at a discount of -160.43% from its 52-week high price of $9.74 and is indicating a premium of 38.5% from its 52-week low price of $2.30. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.61 million shares which gives us an average trading volume of 3.06 million if we extend that period to 3-months.
For Revance Therapeutics Inc (RVNC), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 3.00. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.19 in the current quarter.
Revance Therapeutics Inc (NASDAQ:RVNC) trade information
Upright in the red during last session for losing -0.93%, in the last five days RVNC remained trading in the red while hitting it’s week-highest on Wednesday, 11/27/24 when the stock touched $3.74 price level, adding 11.16% to its value on the day. Revance Therapeutics Inc’s shares saw a change of -57.39% in year-to-date performance and have moved -2.47% in past 5-day. Revance Therapeutics Inc (NASDAQ:RVNC) showed a performance of -36.74% in past 30-days. Number of shares sold short was 12.21 million shares which calculate 4.82 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 17.5 to the stock, which implies a rise of 78.63% to its recent value today. Analysts have been projecting 6.66 as a low price target for the stock while placing it at a high target of 37. It follows that stock’s current price would drop -78.07% in reaching the projected high whereas dropping to the targeted low would mean a loss of -78.07% for stock’s current value.
Revance Therapeutics Inc (RVNC) estimates and forecasts
Statistics highlight that Revance Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company added 31.87% of value to its shares in past 6 months, showing an annual growth rate of 58.75% while that of industry is 17.70. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 6.35% from the last financial year’s standing.
3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 71.73M for the same. And 2 analysts are in estimates of company making revenue of 69.3M in the next quarter. Company posted 69.8M and 51.94M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 0.57% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 40.79% while estimates for its earnings growth in next 5 years are of 11.60%.
Revance Therapeutics Inc (NASDAQ:RVNC)’s Major holders
Insiders are in possession of 8.52% of company’s total shares while institution are holding 81.79 percent of that, with stock having share float percentage of 89.41%. Investors also watch the number of corporate investors in a company very closely, which is 81.79% institutions for Revance Therapeutics Inc that are currently holding shares of the company. CAPITAL WORLD INVESTORS is the top institutional holder at RVNC for having 13.94 million shares of worth $35.82 million. And as of 2024-06-30, it was holding 15.164 of the company’s outstanding shares.
The second largest institutional holder is BLACKROCK INC., which was holding about 8.57 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.3183 of outstanding shares, having a total worth of $22.01 million.
